Alliancebernstein L.P. Design Therapeutics, Inc. Transaction History
Alliancebernstein L.P.
- $290 Billion
- Q2 2025
A detailed history of Alliancebernstein L.P. transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 45,030 shares of DSGN stock, worth $294,045. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,030
Previous 42,090
6.99%
Holding current value
$294,045
Previous $162,000
6.79%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding DSGN
# of Institutions
96Shares Held
33.5MCall Options Held
13KPut Options Held
0-
Sr One Capital Management, LP6.53MShares$42.6 Million7.89% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$27.5 Million1.83% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$15.1 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$12.8 Million0.35% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.81MShares$11.8 Million0.01% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $364M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...